reports
Texas Capital Bancshares, Inc. Appoints Mark Midkiff to Board of Direc...
Texas Capital Bancshares, Inc. Appoints Mark Midkiff to Board of Directors DALLAS, May 16, 2024 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital, today announced the appointment of Mark Midkiff to its Board of Directors, effective June 1, 2024. Midkiff will also serve as a member of the Board’s Risk Committee. Midkiff brings nearly three decades of experience to Texas Capital. Most recently, Midkiff served as chief risk officer at KeyCorp where he reported directly to the CEO. In this role, he oversaw comprehensive risk management fun...
Fluent Announces First Quarter 2024 Financial Results
Fluent Announces First Quarter 2024 Financial Results Revenue of $66.0 million for Q1 2024Net loss of $6.3 million for Q1 2024Gross profit (exclusive of depreciation and amortization) of $18.6 million for Q1 2024Media margin of $22.1 million for Q1 2024Adjusted EBITDA of $0.7 million for Q1 2024Adjusted net loss of $4.2 million for Q1 2024 NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Fluent, Inc. (NASDAQ: FLNT), a leading data-driven performance marketing company, today reported financial results for the first quarter ended March 31, 2024. Don Patrick, Fluent’s Chief Executive Office...
Oncocyte Reports First Quarter 2024 Financial Results
Oncocyte Reports First Quarter 2024 Financial Results Conference Call on Wednesday, May 15, 2024 at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Announced global commercialization partnership with Bio-Rad Laboratories, Inc.On track to ship research use only (RUO) GraftAssure™ transplant monitoring test kits to initial customers in Asia, the U.S., and the EU in 2Q 2024. IVD kits are under development for FDA submission....
Texas Capital Appoints Steve Genyk to Lead New Public Finance Practice
Texas Capital Appoints Steve Genyk to Lead New Public Finance Practice DALLAS, May 15, 2024 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital, today announced that Steve Genyk has joined Texas Capital Securities (TCS), Texas Capital’s broker dealer subsidiary, as Managing Director, Head of Public Finance. In this new role, Genyk is responsible for building out TCS’s Public Finance business, which will provide municipal underwriting services to governments, nonprofits and institutions in the state of Texas and across the country. Ge...
- Wedbush Research
BLUE BLUEBIRD BIO INC.
TPH TRI POINTE HOMES INC.
TOL TOLL BROTHERS INC.
MTH MERITAGE HOMES CORPORATION
LGIH LGI HOMES INC.
LEN LENNAR CORPORATION CLASS A
KBH KB HOME
JACK JACK IN THE BOX INC.
FATE FATE THERAPEUTICS INC
CCS CENTURY COMMUNITIES INC.
BPMC BLUEPRINT MEDICINES CORP.
AZO AUTOZONE INC.
DHI D.R. HORTON INC.
TMHC TAYLOR MORRISON HOME CORPORATION
ORLY O'REILLY AUTOMOTIVE INC.
ACET ADICET BIO INC
BEAM BEAM THERAPEUTICS
COGT COGENT BIOSCIENCES INC
DFH DREAM FINDERS HOMES
NUVB NUVATION BIO INC (A)
TSVT 2SEVENTY BIO INC
GMTX GEMINI THERAPEUTICS INC
PEPG PEPGEN INC
SDHC SMITH DOUGLAS HOMES CORP
- David Carlson
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
IN8bio Announces Upcoming Presentation at 2024 European Hematology Ass...
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced today a presentation at the European Hematology Association 2024 Congress, to be held June 13-16 in Madrid, Spain. “We’re excited to share the latest updated interim results from our Phase 1 trial evaluating our gamma-delta T cell therapy INB-100 after haploidentical stem cell transplantation for patients with leukemia at the upcoming EHA c...
- Wedbush Research
BLUE BLUEBIRD BIO INC.
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TRIP TRIPADVISOR INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
MELI MERCADOLIBRE INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
EXPE EXPEDIA GROUP INC.
AXTI AXT INC.
OSTK OVERSTOCK.COM INC.
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
HPE HEWLETT PACKARD ENTERPRISE CO.
SE SEA ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
BKNG BOOKING HOLDINGS INC.
AVGO BROADCOM INC.
STRO SUTRO BIOPHARMA
LYFT LYFT
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
DELL DELL TECHNOLOGIES INC CLASS C
GBIO GENERATION BIO
DASH DOORDASH
ABNB AIRBNB INC. CLASS A
MRVL MARVELL TECHNOLOGY INC
STX SEAGATE TECHNOLOGY HLDGS PLC
IKNA IKENA ONCOLOGY INC
AVTE AEROVATE THERAPEUTICS INC
DBD DIEBOLD NIXDORF INCORPORATED
- David Carlson
- David Nierengarten
- Dennis Pak
- Martin Fan
Royalty Pharma to Present at Upcoming Investor Conferences
Royalty Pharma to Present at Upcoming Investor Conferences NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: RBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May 14 at 9:00 a.m. ETBofA Securities 2024 Healthcare Conference on Wednesday, May 15 at 6:00 p.m. ET / 3:00 p.m. PT The webcasts will be accessible from Royalty Pharma’s “Events” page at . Webcasts will also be archived for a minimum of thirty days. About Royalty Pharma Fou...
Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and...
Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates Interim data from initial dose escalation cohorts from Phase 1 CARDINAL trial of TERN-701 (allosteric BCR-ABL) in CML expected in 2H24 Top-line data from Phase 1 trial of TERN-601 (oral GLP-1) for obesity expected in 2H24 Cash, cash equivalents and marketable securities of $241 million, expected to provide runway into 2026 FOSTER CITY, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical stage biopharmaceutical company developing...
Oncocyte to Announce First Quarter 2024 Financial Results
Oncocyte to Announce First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, May 15, 2024 at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will release its first quarter 2024 financial results on Wednesday, May 15, 2024, after U.S. market close. The company will host a conference call and webcast on Wednesday, May 15, 2024, at 4:30 p.m. Eastern Time to discuss its financial results and highlights. Interested parties may access the l...
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy...
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024 NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, presented in an oral session details about its robust and reproducible proprietary clinical-scale gamma-delta T cell manufacturing platform across different donor populations, at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting. In an oral presentation titled: “Healthy Donor vs. Patient Manufac...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 20,250 shares of its common stock to eleven newly-hired employees, with a grant date of May 6, 2024 (the "Grant Date"). The restricted stock units were granted pursua...
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Update...
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam $126.3 Million In Total Gross Proceeds from Warrant Distribution.Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam.Over 735 Patients Have Completed a Phase 3 Trial of Simufilam. AUSTIN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial results for first quarter ended March 31, 2024. Net income was $25.0 million compared to a net loss o...
TELA Bio Reports First Quarter 2024 Financial Results
TELA Bio Reports First Quarter 2024 Financial Results MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Reported revenue of $16.6 million in the first quarter, representing growth of 39% over the prior year period of 2023;Delivered the 13th consecutive quarter of at least 35% year-over-year growth;Increased demand for OviTex® and OviTex PRS Reinforced Tis...
IN8bio Reports First Quarter 2024 Financial Results and Recent Corpora...
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - Presented new preclinical data demonstrating proof-of-concept for non-signaling Chimeric Antigen Receptor (nsCAR) platform to effectively target cancer cells while preserving healthy tissue - Demonstrated potential of nsCAR platform to treat previously “undruggable” solid and liquid tumor targets - Announced peer-reviewed publication in ‘Frontiers in Immunology’ on IN8bio’s DeltEx Drug Resistant Immunotherapy (DRI) approach to newly diagnosed glioblastoma multiforme (GBM) - Dosed first patient in auto...
Fluent, Inc. to Announce 2024 First Quarter Financial Results on May 1...
Fluent, Inc. to Announce 2024 First Quarter Financial Results on May 15, 2024 NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Fluent, Inc. (NASDAQ: FLNT) announced today that it will report its financial results for the First Quarter 2024 after the close of the U.S. financial markets on May 15, 2024. Fluent will host a conference call at 4:30 pm ET on the same day to discuss the results. The conference call can be accessed by phone after registering online at or via audio at . The call will also be webcast simultaneously on the Fluent website on the . Please log in at least 15 minutes prior...
- Jonathan Chaplin
SATS: model update
This note covers updates to the model following consolidated EchoStar results. We increased service revenue and EBITDA. Our free cash flow is up very modestly. The company has five to seven months to raise capital. We updated our valuation to $95 / share. We will have another update out once we get the Dish, DBS & Hughes 10-Qs.
- David Carlson
- David Nierengarten
- Dennis Pak
- Martin Fan
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.